An increasing shift towards non-invasive and minimally-invasive treatments, such as facial rejuvenation and non-surgical fat reduction, is also driving driving demand for aesthetic medicines.
The International Society of Aesthetic Plastic Surgery estimates that over 21.6 million non-surgical aesthetic/cosmetic procedures were performed worldwide in 2015.
Furthermore, advantages of minimally-invasive surgeries over invasive surgeries – including reduced hospital stays, smaller incisions, curtailed risk of infections, lower operative pain and discomfort, and minimised risk of complications such as blood loss – will further stimulate aesthetic medicine market growth over the coming years.
Rising demand for non-surgical aesthetic procedures among men, coupled with intensified spending on aesthetic procedures, will further augment demand and fuel industry expansion.
A total of 881,663 non-surgical procedures such as botulinum toxin injections and fat reduction were performed on male patients in 2013, accounting for for 9.2% of the total surgeries, according to the American Society for Aesthetic Plastic Surgery.
Facial aesthetics segment dominated the aesthetic medicine industry in 2017, owing to the rising usage and demand for botulinum toxin and dermal fillers used to treat deep wrinkles, crow’s feet, chin dimpling, acne scars, lip augmentation and lipoatrophy in face.
An increasing shift towards minimally-invasive procedures, along with rising geriatric patient pool, will further contribute to amplify segmental market share.